ezh2 oncogenic activity castration-resistant prostate cancer cells polycomb-independent 
epigenetic regulators represent promising new class therapeutic targets cancer enhancer zeste homolog ezh2 subunit polycomb repressive complex prc2 silences gene expression via histone methyltransferase activity found oncogenic function ezh2 cells castration-resistant prostate cancer independent role transcriptional repressor instead involves ability ezh2 act coactivator critical transcription factors including androgen receptor functional switch dependent phosphorylation ezh2 requires intact methyltransferase domain hence targeting non-prc2 function ezh2 may therapeutic efficacy treating metastatic hormone-refractory prostate cancer 
